MetLife's stock behaviour and
valuation showed mixed results due its
recent share price performance. Despite this, analysts exhibit optimistic views on the company's performance.
MetLife's investment arm made a significant play in private deals worth
$26bn in 2025. However, the company missed its Q4 CY2025 revenue estimates. Some noteworthy transactions saw
Cantor Fitzgerald Investment Advisors selling a considerable number of shares. On a more positive note,
MetLife outlined its Q1 2026 variable investment income outlook and Wall Street Zen upgraded its rating on the company.Despite the cut in the price target by some institutions, others made new investments and raised their price targets. MetLife was also able to expand its portfolio with $26B in
Private Fixed Income Deals and originates $26B in private fixed income transactions over the last year. While the recent share price weakness and valuation signals raise questions about whether MetLife is an attractive buy, there are still bullish sentiments with regard to
MetLife's probable performance post its Q4 earnings.
Metlife MET News Analytics from Thu, 11 Sep 2025 07:00:00 GMT to Sat, 11 Apr 2026 21:29:51 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor -8
